Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


92 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

CSL, CSL LIMITED
nipper
post Posted: Jun 25 2020, 05:32 PM
  Quote Post


Posts: 7,081
Thanks: 2433


Hot on the heels of its decision to acquire clinical-stage biotechnology company Vitaeris earlier this month, this morning the company announced plans to make another acquisition.

CSL has agreed to acquire the exclusive global license rights to commercialise an adenoassociated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of haemophilia from Nasdaq-listed gene therapy company, uniQure .

According to the release, the AMT-061 program, which is currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with haemophilia B.

Management explained that one dose of AMT-061 has shown to increase Factor IX (FIX) plasma levels to a degree that reduces or eliminates the tendency for bleeding for many years. FIX is the blood clotting protein lacking in people with haemophilia B.

This means that should AMT-061s trials be successful, appropriate candidate haemophilia B patients will be able to have a one-time treatment to restore FIX activity to functional levels capable of eliminating the need for frequent and ongoing replacement therapies.

CSLs CEO and Managing Director, Paul Perreault, commented: Our vision for haemophilia B patients is to offer transformational treatment paradigms that help free them from the lifelong burden of this disease. With more than three decades of providing lifesaving innovations for the global bleeding disorders community, we are well positioned to maximise the potential benefit of this therapy.

What is CSL paying for AMT-061?

Under the agreement with the gene therapy company, CSL will have the exclusive global right to commercialise AMT-061.

It will pay uniQure an upfront cash payment of US$450 million, followed by regulatory and commercial sales milestone payments and royalties.

In addition, uniQure will complete the Phase 3 trial and scale up manufacture for early commercial supply under an agreed plan with CSL. The transaction remains subject to customary regulatory clearances before closing.

Mr. Perreault concluded: Upon approval, we believe this next-generation therapy would be highly complementary to our existing haemophilia B product portfolio. We hope that it provides patients with an alternate best-in-class treatment option, building on our legacy of delivering lifesaving innovations in hematology."



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jun 5 2020, 09:00 PM
  Quote Post


Posts: 7,081
Thanks: 2433


QUOTE
Australias biggest health company, CSL, says it can produce up to 100 million doses of a COVID-19 vaccine by the end of next year if clinical trials in Australia and in high-infection areas overseas are successful.

CSL has struck a partnership with the Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI) and University of Queensland to fast-track the development of a COVID-19 vaccine, catapulting it to the forefront of the global battle to fight the coronavirus.

But CSL chief executive Paul Perrault said that while the company and UQ had won international endorsement, it was not a race against other vaccines in development.

This is a race against the virus and there will be multiple vaccines to supply the globe, Mr Perrault said. We dont know enough about the virus today to know how long it will be around, if there will have to be additional doses of vaccines in the future, and so it is imperative that everybody work as hard as they can collaboratively. The agreement formalises CSLs commitment to lend all its resources to UQs vaccine research effort, and comes 25 years after CSL and UQ partnered to develop the cervical cancer vaccine Gardasil.

Meanwhile, CEPI has provided UQ up to $US10.6m ($15.16m) to develop its molecular clamp vaccine platform, a transformative technology patented by UniQuest, UQs technology transfer company, that enables rapid vaccine design and production.

Already early preclinical results in mice have shown their COVID-19 vaccine candidate produces high levels of antibodies that can neutralise the virus, which has killed 383,000 people worldwide.

UQ is now on track to launch a phase 1 clinical trial next month, which will involve 120 patients, and be funded by CSL and CEPI. While initial results are promising, Mr Perrault cautioned that there was no guarantee of success.

Research is risky, even at the best of times, he said. While initial results from UQs research are very promising there remains a number of critical milestones ahead before we can declare victory with an effective and safe vaccine to protect people from COVID-19.

The phase 1 trial will test the safety of the vaccine and also help determine the correct dosage. If that is successful, the vaccine will proceed to phase 2 trials, involving 800-1000 people.

UQ professor Paul Young said that unlike the phase 1 trial, which would be conducted in Brisbane, the phase 2 trial would be performed overseas.

Fortunately right now in Australia the infection rate is pretty low, which is great. But to do the phase 2 efficacy study we need to do it in parts of the world or a part of the world where there are infections taking place, Professor Young said.

We are looking very hard with the clinical team now at which countries or cities the studies be done. It will have to be done where there are both infections but also where there is good health infrastructure and where we can gather high-quality data.

CSL chief scientific officer Andrew Cuthbertson said the company hadnt budgeted the full cost of the vaccine development.

UQ vice-chancellor Peter Hoj said the vaccine development was at a critical juncture.

CEPI chair Jane Halton said multiple vaccine research efforts were needed to defeat the virus.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jun 2 2020, 10:22 AM
  Quote Post


Posts: 7,081
Thanks: 2433



QUOTE
CSL is searching for plasma from recovered coronavirus patients as companies across the United States turn to higher payment rates and free rides to lure donors into collection centres.

The exact going rate for this plasma is not known, with CSL saying the value depends on a number of factors, including location and demand. However, plasma donations tend to pay as much as $US50, or up to $US70 to first-time donors and those with in-demand antibodies.

"Recovered COVID-19 donors are compensated at the same level as other speciality plasma programs (such as Anti-D and Rabies), which is at a slightly higher rate than normal donors," a CSL spokeswoman said....

Over the past month, collectors across the US have been urging donors to return to centres, assuring them coronavirus safety measures are in place. The sector has also launched a campaign for American donors called "The Fight is in Us" to encourage those that have beaten COVID-19 to donate.

"In support of those donors, the Global Plasma Alliance (which CSL is a member of) has partnered with ride sharing service, Uber, to provide complementary rides to and from plasma collection centres for those who are potentially eligible to donate convalescent COVID-19 plasma," a CSL spokeswoman said.

CSL is also collecting recovered donor plasma in Australia, though these donors will not get paid. It needs about 10 per cent of the 6000 Australians who have recovered from the virus to donate at least once so it can start research into a hyperimmune treatment. It said while early donations have been promising, more are needed.







--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne

Said 'Thanks' for this post: early birds  rlane  
 
nipper
post Posted: Apr 7 2020, 01:21 PM
  Quote Post


Posts: 7,081
Thanks: 2433


Covid-19 response
QUOTE
Clinical trials of unbranded hyperimmune serum could begin ­“within months”, CSL chief scientific ­officer Andrew Cuthbertson said. An effective vaccine able to protect the entire population takes at least 12 months to ­develop.

Professor Cuthbertson said well-designed trials would guide decisions about who would be first in the queue for serum treatment, which is based on “borrowing” the antibodies of patients whose immune systems have fought off the viral illness.

“Probably people who are very high risk, maybe people who are infected and getting worse and heading for the ­intensive care unit, possibly in the ICU. “It could also be used as a preventative treatment if someone coughed right into the face of a health worker.”

Debate on priorities

He said priorities for eligibility in trials and for treatment would involve “great debate”.

“It’s a matter of how do we best use these precious initial vials of this medicine, because we won’t be able to make enough to protect the entire population — you need a vaccine to do that.”

The global pooling of expertise and resources for the manufacture of the hyperimmune treatment was announced on Monday night, with CSL subsidiary CSL Behring and Takeda joined by the German-headquartered Biotest, LFB (France), Octapharma (Switzerland) and Bio Products Laboratory (Britain).

The humanitarian alliance between commercial rivals is open to other firms and plans to work with governments.

“Unprecedented times call for bold moves,” said Julie Kim, president of Takeda’s Plasma-Derived Therapies Business Unit.

Professor Cuthbertson said he expected clinical trials in the northern hemisphere and Australia could start in parallel, with sharing of data and insights speeding up progress.

He said local trials might require 100 to 500 donors, and would require the development of tests enabling identification of the best donors and the potency of antibodies against the illness.

CSL was in talks with the federal Health Department, regulator Therapeutic Goods Administration, research partners including the Melbourne-based Peter Doherty Institute for Infection and Immunology, and plasma collection agency the Australian Red Cross Lifeblood to get trials on foot as soon as possible.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Feb 12 2020, 07:43 AM
  Quote Post


Posts: 7,081
Thanks: 2433


CSL achieved 11 per cent net profit growth of $US1.248 billion and earnings of $US2.75 a share.

The company declared an interim dividend of US95¢ and forecast 2019-20 net profit of $US2.11 billion to $US2.17 billion, up 10 to 13 per cent year-on-year



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Feb 6 2020, 09:09 AM
  Quote Post


Posts: 7,081
Thanks: 2433


In Reply To: nipper's post @ Jan 16 2020, 09:09 AM

and through $320.

(being in the flu vaccine biz, with a coronavirus around, wouldn't be hurting)




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 

Featured Stock Stories





nipper
post Posted: Jan 16 2020, 09:09 AM
  Quote Post


Posts: 7,081
Thanks: 2433


well, CSL hit $300.00 soon after the opening bell this morning.
There was a quick retreat from there, almost to be expected. Mere observer sport, really, but something to write about




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 6 2020, 01:20 PM
  Quote Post


Posts: 7,081
Thanks: 2433


QUOTE
A research note out of Morgan Stanley suggests CSL shares could hit $290 over the next 12 months with a bull case valuation of $359. The key to the bull case valuation is the healthcare giant's Phase 3 trial drug candidate CSL 112 as a treatment for heart attack patients.

It has three potential "catalytic events" over the next 18 months according to the analysts.

Morgan Stanley is forecasting the group will deliver $US4.68 in earnings per share (EPS) over fiscal 2020 on revenue of US$9,129 million. For fiscal 2021 it expects EPS to climb to $US5.50 on revenue of $US10,231 million.

In total it's tipping growing immunoglobulin sales to help deliver a 3-year compound EPS annual growth rate of 13 per cent with fiscal 2020 "above or at the top end of guidance.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 30 2019, 09:37 AM
  Quote Post


Posts: 7,081
Thanks: 2433


Heart-stopper: CSL's $800m heart attack trial
As far as investments go, CSL Limited's $800 million all-or-nothing bet on a treatment to stop recurrent cardiovascular events is a heart-stopper.

http://www.smh.com.au/business/heart-stopp...53iog.html?btis



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
plastic
post Posted: Dec 19 2019, 05:01 PM
  Quote Post


Posts: 10,060
Thanks: 299


In Reply To: mullokintyre's post @ Dec 19 2019, 01:59 PM

A misspelled one. Doesn't detract from the point I make however. The point of confusion was that both were/are federally sponsored. As are NZ's CRI's.

Imagine how the original investors must be feeling now. They must be in all the best graveyards around town.




--------------------
What did Uncle Mel do to us?
 
 


92 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING